The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...